Skip to content

Comparing the effect of sevelamer carbonate and sevelamer hydrochloride on blood level of phosphate, Ca, ph, bicarbonate and gastrointestinal complications in patients undergoing maintenance hemodialysis

Comparing the effect of sevelamer carbonate and sevelamer hydrochloride on blood level of phosphate, Ca, ph, bicarbonate and gastrointestinal complications in patients undergoing maintenance hemodialysis

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20141016019554N13
Enrollment
44
Registered
2018-02-17
Start date
2017-03-21
Completion date
Unknown
Last updated
2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Calcium, Phosphorus, PH, Bicarbonate and Gastrointestinal Complications in Hemodialysis Patients. Chronic kidney disease, stage 4 (severe)

Interventions

Intervention 1: Intervention group 1: 800 mg Sevelamer Carbonate triple time daily with each meal for 1 month. Intervention 2: Intervention group 2: Sevelamer Hydrochloride 800 mg triple daily with ea

Sponsors

Zanjan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who undergo dialysis three sessions each week for four hours each day. Their blood phosphorus level is higher than 5.5 mg / dL.

Exclusion criteria

Exclusion criteria: Patients who have not taken limited Phosphorus diet. Patients who lose their ability to participate during the study Patients who are absent from dialysis session Patients who break their access for some reason Patients who have taken the medication inappropriately. Patients with a history of primary hyperparathyroidism or history of parathyroidectomy. Patients with a history of gastrointestinal diseases include peptic ulcer, reflux, and constipation Patients with a history of congestive heart failure (due to electrolyte imbalance) Patients with chronic obstructive pulmonary disease (COPD) (due to acid and basis disorders).

Design outcomes

Primary

MeasureTime frame
Blood Calcium. Timepoint: at beginning of intervention and 1 month later. Method of measurement: measurement will be carried out by hospital laboratory.;Blood Phosphorus. Timepoint: at beginning of intervention and 1 month later. Method of measurement: measurement will be carried out by hospital laboratory.;Blood pH. Timepoint: at beginning of intervention and 1 month later. Method of measurement: measurement will be carried out by hospital laboratory.;Blood Bicarbonate levels. Timepoint: at beginning of intervention and 1 month later. Method of measurement: measurement will be carried out by hospital laboratory.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBehrooz Fazeli

Zabol University of Medical Sciences

dr.behroozfazeli@zums.ac.ir+98 919 674 7560

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 13, 2026